Priovant Therapeutics, a Roivant unit, won FDA approval for Lisraya (brepocitinib) to treat dermatomyositis, marking a first regulatory nod for a once-daily, oral approach designed to block JAK1 and TYK2. The clearance expands the therapeutic options for a rare autoimmune condition historically managed with high-dose steroids and other immunosuppressants. The FDA’s decision positions brepocitinib for commercial launch as the first oral therapy in this category of patients, while also potentially reshaping standard-of-care pathways given the steroid-sparing goal in dermatomyositis management. Roivant has additionally described further clinical development plans across other rare inflammatory indications. For investors and clinicians, the approval provides a near-term benchmark for the differentiation of JAK/TYK axis inhibition in dermatomyositis versus existing immunomodulatory strategies.